November 2020
TACTI-Mel (Efti and Keytruda) phase 1 - 24 patients with advanced melanoma.
Safety and dose escalation - primary endpoints
But note efficacy - 66% of patients progression free after 6 months. (follow-up 12 month PFS data due circa May 2021).
BMS - Opdivo and Relatlimab (PD-1 and anti Lag-3) combo in melanoma P3 - 700 patients met PFS goal (not yet disclosed).
Of interest - Opdivo in combo with Yervoy (PD-1 and CTLA checkpoint inhibitors) - 33% patients progression free after 12 months.
90 cents is the price target, page-14
-
- There are more pages in this discussion • 114 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
40.0¢ |
Change
-0.005(1.23%) |
Mkt cap ! $581.0M | |||
| Open | High | Low | Value | Volume |
| 41.0¢ | 41.5¢ | 39.5¢ | $1.576M | 3.906M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2506 | 39.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 40.0¢ | 8079 | 1 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| IMM (ASX) Chart |